ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions

View by Date

Sunday, November 8, 2020

3:00PM-3:50PM: Abstract Number: 1466

Multimorbidity in Rheumatoid Arthritis, Psoriatic Arthritis, Gout, and Osteoarthritis Within the Rheumatology Informatics System for Effectiveness (RISE) Registry

Epidemiology & Public Health I: RA (1462–1466)

3:00PM-3:50PM: Abstract Number: 1501

Obstetrical Outcome and Thromboses in a Multicentric Cohort of Antiphospholipid Syndrome (APS) Patients with Severe Preeclampsia: An Analysis of APS Classification Criteria

Reproductive Issues in Rheumatic Disorders (1497–1501)

3:00PM-3:50PM: Abstract Number: 1510

Platelet-bound C4d Is Associated with Platelet Activation and Arterial Thrombotic Events

SLE – Diagnosis, Manifestations, & Outcomes II: Bench to Bedside (1507–1511)

3:00PM-3:50PM: Abstract Number: 1498

Pregnancy Outcomes in Patients with Axial Spondyloarthritis – a First Analysis of a European Collaboration of Pregnancy Registries

Reproductive Issues in Rheumatic Disorders (1497–1501)

3:00PM-3:50PM: Abstract Number: 1523

Pulmonary Cytokine, Chemokine and Growth Factor Profiles of Distinct Radiographic Patterns of Interstitial Lung Disease in Systemic Sclerosis

Systemic Sclerosis & Related Disorders – Basic Science (1522–1526)

3:00PM-3:50PM: Abstract Number: 1526

Single Cell Analysis of Skin and Blood of Scleroderma Patients Towards Identification of New Disease Mechanisms, Prognostic Biomarkers and Potential Therapeutic Targets

Systemic Sclerosis & Related Disorders – Basic Science (1522–1526)

3:00PM-3:50PM: Abstract Number: 1499

The Frequency of Contraception Documentation in Women with Lupus and Rheumatoid Arthritis Within the RISE Registry

Reproductive Issues in Rheumatic Disorders (1497–1501)

3:00PM-3:50PM: Abstract Number: 1465

The Impact of the Combined Vaccination Scheme Against Streptococcus Pneumoniae on the Incidence of Related Infections in Patients with Rheumatoid Arthritis Treated with Biologic or Targeted Synthetic DMARD: Data from BIOBADASER 3.0

Epidemiology & Public Health I: RA (1462–1466)

3:00PM-3:50PM: Abstract Number: 1463

Threshold Level for Long-term Healthy Diet Adherence to Reduce the Risk of Rheumatoid Arthritis Among Women in a Prospective Cohort Using a Marginal Structural Model Approach

Epidemiology & Public Health I: RA (1462–1466)

4:00PM-4:50PM: Abstract Number: 1483

A Randomised Controlled Trial Evaluating the Efficacy of Internet-based Exercises Aimed at Treating Knee Osteoarthritis (iBEAT-OA)

Osteoarthritis I: Clinical Trials (1482–1486)

4:00PM-4:50PM: Abstract Number: 1449

Altered Splicing in Leukocytes from Patients with Antiphospholipid Syndrome, Systemic Lupus Erythematosus and Antiphospholipid Syndrome with Lupus: Clinical Involvement

Antiphospholipid Syndrome (1447–1451)

4:00PM-4:50PM: Abstract Number: 1469

Characteristics of Adult Patients with Rheumatic Diseases During the COVID-19 Pandemic: Data from an International Patient Survey

Epidemiology & Public Health II: Risk Factors & Outcomes (1467–1471)

4:00PM-4:50PM: Abstract Number: 1493

Distinct Patient-level Patterns of Response to Methotrexate in Juvenile Idiopathic Arthritis

Pediatric Rheumatology – Clinical I: Treatment of JIA (1492–1496)

4:00PM-4:50PM: Abstract Number: 1467

Effectiveness of the Making It Work™ Program at Improving Presenteeism and Work Cessation in Workers with Inflammatory Arthritis – Results of a Randomized Controlled Trial

Epidemiology & Public Health II: Risk Factors & Outcomes (1467–1471)

4:00PM-4:50PM: Abstract Number: 1484

Efficacy of Tocilizumab in Patients with Hand Osteoarthritis: Double Blind, Randomized, Placebo Controlled, Multicenter Trial

Osteoarthritis I: Clinical Trials (1482–1486)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].